🔬 New preprint: How does the mode of oncogene activation shape PROTAC efficacy? Led by Evelina Gudauskaite, we ask whether stabilising mutations vs transcriptional upregulation have distinct consequences for targeted protein degradation. www.biorxiv.org/content/10.6....

🔬 New preprint: How does the mode of oncogene activation shape PROTAC efficacy? Led by Evelina Gudauskaite, we ask whether stabilising mutations vs transcriptional upregulation have distinct consequences for targeted protein degradation. www.biorxiv.org/content/10.6....

Congratulations to Tom Deegan who receives the Colworth Medal in 2027! Pioneering work from the Deegan Lab has redefined our understanding of eukaryotic DNA replication and provided conceptual and technical frameworks that continue to drive new discoveries across molecular biology.

Online now! Online now! Assessing the suitability of deubiquitylases as substrates for targeted protein degradation #chembiol

An elegant approach using a mix of technologies and making the most of resources generated over many years of research into the canonical Wnt pathway. And results which have the potential to andvance personalised treatment for some forms of cancer. Congrats @andrewwood.bsky.social and collaborators!

Read more about a new map showing how hundreds of possible mutations in a key cancer gene influence tumour growth 👉 edin.ac/3NTaToX @andrewwood.bsky.social @roslininstitute.bsky.social @unileiden.bsky.social @koc-university.bsky.social @cmvm-edinburghuni.bsky.social

Today in @natgenet.nature.com, we report a saturation genome editing study that systematically dissects the degron of β-Catenin, which contains 5 of the 25 most frequently mutated regions of the human cancer genome, and >70 recurrent missense mutations. rdcu.be/e1Tvk

Our Best Models Working Group can offer advice on the use of a range of model systems. The next in our series highlighting our diverse expertise features Dr Andrew Wood, whose lab uses genome editing and targeted protein degradation to study genetic disease using cell lines, organoids, and mice.

Today's a good day to remember Rosalind Franklin, British chemist and X-ray crystallographer whose untimely death meant three men shared a Nobel prize for discovering the structure of DNA for which she'd done most of the work.

With storm Amy approaching, it’s an ideal time to get your SLiPERs on!

On 14th November, we are once again holding our Network Science Day in York, which is an exciting opportunity for Network members and non-members to engage and develop new collaborations! The meeting is free to attend. Find out more and register by emailing us at [email protected].

Look at this crazy thing! www.nature.com/articles/s41...

Our manuscript characterising tissue-specific consequences of tagged protein fusions in CRISPR-engineered mice is now online @PLOSGenetics. journals.plos.org/plosgenetics.... Thanks again to all coauthors, reviewers and editors for a smooth publication process. Brief summary below.

Oliver Smithies was born 100 years ago today. Best known for gene targeting in mice, for which he shared the 2007 Nobel, he also developed starch gel electrophoresis in the 1950s. I met him once and remember him being very gracious and thoughtful. #genetics #OTD www.nobelprize.org/prizes/medic...

Pleased to share our latest work and the first manuscript from the Degron Tagging Cluster in the MRC National Mouse Genetics Network. If you work with protein tags, particularly in tissue biology models, this should be of interest: www.biorxiv.org/content/10.1...

New paper out in Genome Biology! 🎉 We lay out best-practice guidelines for releasing variant effect predictors, developed through the Atlas of Variant Effects Alliance @varianteffect.bsky.social Open, interpretable, and clinically useful VEPs are the goal. 📄 doi.org/10.1186/s130...

The first bifunctional protein degrader to deliver Phase III data! It seems to work, but people were definitely expecting more:

www.nature.com/articles/d41... #RIPTACs

ICYMI: Commentary on "mechanism" in dev bio Ozpolat et al argue for diverse approaches to mechanism - from molecular to systems level journals.biologists.com/dev/article/...

Every once in a while we publish a paper that moves a whole field forward. I think that's the case for this one from the Bugaj lab, where they describe proteins for THERMOGENETIC control of cellular behavior. www.nature.com/articles/s41...

🧪 Ready, set, degrade! So proud to share our work in the @jclinical-invest.bsky.social, establishing a versatile approach for creating transgenic dTAG mice to degrade oncoproteins. We showcase that KRAS G12V degradation triggers antitumor immunity in lung cancer. Link: www.jci.org/articles/vie...

🧪1/ 🚨New paper on ecDNAs from our lab! We reveal a strategy to engineer extrachromosomal DNA (ecDNA) amplifications in cells & mice. Let's dive in! Let’s dive in! 🧵👇 www.nature.com/articles/s41...

Americans are now one-third less likely to die from cancer at the same ages as Americans in 1990

Essential reading for all that serve as reviewers. Please help your authors as if they were in your lab. Make your reviews constructive. Overly onerous reviews amount to blocking each others’ work. It slows progress and demoralizes junior investigators. Let’s elevate, not crush, #DevBio

New spinout Trogenix unveils its novel treatment platform that targets aggressive cancers, including brain cancer. IRR's Professor Steven Pollard is co-founder and Chief Scientific Officer #Cancer #RegenerativeMedicine #CRM regeneration-repair.ed.ac.uk/news/irr-new...

Seems that @biorxivpreprint.bsky.social ought to consider adding links to @bsky.app posts given the mass transfer of scientists from Twitter to @bsky.app that is taking place.